Product References
Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study.
Neuro-oncology
Jakacki RI,Cohen KJ,Buxton A,Krailo MD,Burger PC,Rosenblum MK,Brat DJ,Hamilton RL,Eckel SP,Zhou T,Lavey RS,Pollack IF
MA3-16537 was used in immunohistochemistry - paraffin section to analyze the Children's Oncology Group ACNS0423 phase 2 study of concurrent temozolomide and radiotherapy followed by lomustine and temozolomide in treatment of children with high-grade glio
Sat Oct 01 00:00:00 UTC 2016
Glioma Cells in the Tumor Periphery Have a Stem Cell Phenotype.
PloS one
Munthe S,Petterson SA,Dahlrot RH,Poulsen FR,Hansen S,Kristensen BW
MA3-16537 was used in immunohistochemistry - paraffin section to study tumor periphery glioma cells and their stem cell phenotype
Mon Jul 10 00:00:00 UTC 2017
Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide.
The Journal of clinical endocrinology and metabolism
Bengtsson D,Schrøder HD,Andersen M,Maiter D,Berinder K,Feldt Rasmussen U,Rasmussen ÅK,Johannsson G,Hoybye C,van der Lely AJ,Petersson M,Ragnarsson O,Burman P
MA3-16537 was used in immunohistochemistry - paraffin section to discuss the use of temozolomide to treat pituitary tumors
Wed Apr 01 00:00:00 UTC 2015
MGMT expression and pituitary tumours: relationship to tumour biology.
Pituitary
McCormack A,Kaplan W,Gill AJ,Little N,Cook R,Robinson B,Clifton-Bligh R
MA3-16537 was used in immunohistochemistry to perform a comparative study the gene expression profiles and cancer biology of pituitary tumors classified as high or low expressors of MGMT
Sat Jun 01 00:00:00 UTC 2013
Hsp27 (HSPB1): a possible surrogate molecular marker for loss of heterozygosity (LOH) of chromosome 1p in oligodendrogliomas but not in astrocytomas.
Cell stress & chaperones
Castro GN,Cayado-Gutiérrez N,Moncalero VL,Lima P,De Angelis RL,Chávez V,Cuello-Carrión FD,Ciocca DR
MA3-16537 was used in immunohistochemistry (paraffin) to examine heat shock proteins in different subtypes of gliomas.
Thu Nov 01 00:00:00 UTC 2012
O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation is a rare event in soft tissue sarcoma.
Radiation oncology (London, England)
Jakob J,Hille M,Sauer C,Ströbel P,Wenz F,Hohenberger P
MA3-16537 was used in immunohistochemistry to study the frequency of MGMT promoter methylation in soft tissue sarcomas
Tue Oct 30 00:00:00 UTC 2012
O6-Methylguanine-DNA methyltransferase protein expression by immunohistochemistry in brain and non-brain systemic tumours: systematic review and meta-analysis of correlation with methylation-specific polymerase chain reaction.
BMC cancer
Brell M,Ibáñez J,Tortosa A
MA3-16537 was used in flow cytometry and immunohistochemistry to review methods to analyze O6-Methylguanine-DNA methyltransferase
Wed Jan 26 00:00:00 UTC 2011
Impact of morphology, MIB-1, p53 and MGMT on outcome in pilocytic astrocytomas.
Brain pathology (Zurich, Switzerland)
Horbinski C,Hamilton RL,Lovell C,Burnham J,Pollack IF
MA3-16537 was used in immunohistochemistry - paraffin section to discuss indicators of tumor aggressiveness for pilocytic astrocytoma
Sat May 01 00:00:00 UTC 2010
Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases.
European journal of endocrinology
Losa M,Mazza E,Terreni MR,McCormack A,Gill AJ,Motta M,Cangi MG,Talarico A,Mortini P,Reni M
MA3-16537 was used in immunohistochemistry to discuss the therapeutic benefic of temozolomide treatment in patients with aggressive or metastatic pituitary adenomas
Wed Dec 01 00:00:00 UTC 2010
Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours.
Clinical endocrinology
McCormack AI,McDonald KL,Gill AJ,Clark SJ,Burt MG,Campbell KA,Braund WJ,Little NS,Cook RJ,Grossman AB,Robinson BG,Clifton-Bligh RJ
MA3-16537 was used in immunohistochemistry to investigate the association between O6-methylguanine-DNA methyltransferase expression and temozolomide therapy in aggressive pituitary tumours
Sat Aug 01 00:00:00 UTC 2009
Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours.
Clinical endocrinology
McCormack AI,McDonald KL,Gill AJ,Clark SJ,Burt MG,Campbell KA,Braund WJ,Little NS,Cook RJ,Grossman AB,Robinson BG,Clifton-Bligh RJ
MA3-16537 was used in immunohistochemistry to investigate the association between O6-methylguanine-DNA methyltransferase expression and temozolomide therapy in aggressive pituitary tumours
Sat Aug 01 00:00:00 UTC 2009
Prognostic significance of DNA repair proteins MLH1, MSH2 and MGMT expression in non-small-cell lung cancer and precursor lesions.
Histopathology
Cooper WA,Kohonen-Corish MR,Chan C,Kwun SY,McCaughan B,Kennedy C,Sutherland RL,Lee CS
MA3-16537 was used in immunohistochemistry - paraffin section to investigate the role of DNA repair proteins and their prognostic significance in non-small-cell lung cancer
Tue Apr 01 00:00:00 UTC 2008